|Anti-mPD-1-mIgG1e3 InvivoFit™||Unit size||Cat. code||Docs||Qty||Price|
RMP1-14-derived mouse monoclonal antibody against murine PD-1
Recombinant mouse mAb against murine PD-1
Anti-mPD-1-mIgG1e3 InvivoFit™ is a recombinant monoclonal antibody (mAb) featuring the variable region of the previously described anti-mPD-1 RMP1-14 mAb [1, 2]. The original RMP1-14 hybridoma was obtained by immunizing rats with cells expressing murine programmed cell death 1 (mPD-1; also known as CD279). The rat origin of this mAb renders it immunogenic upon injection in mice. To overcome this issue, Anti-mPD-1-mIgG1e3 InvivoFit™ was generated by recombinant DNA technology so that it is ~85% murine. It contains the constant region of mouse IgG1 with a D265A point mutation (replacement of aspartic acid by alanine at position 265) resulting in the complete loss of cytolytic effector function [2, 3]. Anti-mPD-1-mIgG1e3 is provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo studies.
Anti-mPD-1-mIgG1e3 InvivoFit™ is specifically designed for in vivo studies in mice:
- Sequence is ~85% mouse origin (constant region) and ~15% rat origin (variable region)
- Features the effectorless IgG1e3 (IgG1 with a D265A point mutation)
- Blocks the murine PD-1 receptor without causing T cell depletion
- Guaranteed sterile, endotoxin level: 1 EU/mg
- Suitable for parenteral delivery in mice (azide-free)
- Low aggregation < 5%
- Produced in both animal-free facilities and defined media
Anti-mPD -1-mIgG1e3 InvivoFit™ is produced in Chinese hamster ovary (CHO) cells and purified by affinity chromatography with protein A. Its binding is validated by flow cytometry and ELISA.
1. Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.
2. Yamazaki T. et al., 2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92.
3. Baudino L. et al., 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol. 181(9):6664-9.
ELISA binding of Anti-mPD-1-mIgG1e3 InvivoFit™ to recombinant murine PD-1.
A dilution series of Anti-mPD-1-mIgG1e3 InvivoFit™ and anti-mPD-1 (clone RMP1-14) was used for detection of coated mPD-1 antigen at 2 µg/ml. Detection of bound antibody was performed using an HRP-conjugated anti-murine IgG secondary antibody for Anti-mPD-1-mIgG1e3 InvivoFit™ and an HRP-conjugated anti-rat IgG2a secondary antibody for anti-mPD-1 (clone RMP1-14). HRP activity was measured by a colorimetric assay using Tetramethylbenzidine (TMB) substrate. Optical density was measured at 490 nm. Data are shown as percentage absorbance.
Specificity: Targets cells expressing murine PD-1
Formulation: Lyophilized from 0.2 μm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharose
Clonality: Monoclonal antibody
Isotype: Murine IgG1e3 (D265A mutation; no effector function)
Source: CHO cells
Purity: Purified by affinity chromatography with protein A
Tested applications: Flow cytometry and ELISA
- Binding confirmed by flow cytometry
- The complete sequence of this antibody has been verified
- < 5% aggregates (confirmed by size exclusion chromatography)
- Guaranteed sterile and <1 EU/mg (determined by the LAL assay)
Anti-mPD-1-mIgG1e3 InvivoFit™ is provided sterile, endotoxin-free, azide-free and lyophilized.
This product is available in two pack sizes:
- mpd1-mab15-1: 1 mg
- mpd1-mab15-10: 10 mg
Product is shipped at room temperature.
Store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year
Avoid repeated freeze-thaw cycles.Back to the top
Programmed cell death 1 (PD-1; also known as CD279) is a type I transmembrane protein expressed at the cell surface of activated and exhausted conventional T cells. PD-1 is an inhibitory immune checkpoint that prevents T-cell overstimulation and host damage.
PD-1 interaction with its ligands PD-L1 (programmed cell death ligand 1) or PD-L2 induces inhibition of T-cell receptor signaling. Blockade of PD-1 with mAbs has allowed unprecedented remissions in patients with metastatic melanoma or non-small cell lung cancer.